The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Rapid Response Innovation Awards, 2011Alpha-Synuclein Knockdown: Therapeutic or Toxic?
Objective/Rationale:
The protein alpha-synuclein (a-syn) has been conclusively linked to Parkinson’s disease. The prevailing theory today states that a-syn is a causative agent in the development of... -
Improving Levodopa Delivery, 2011Dry Powder-Based Delivery of Intrapulmonary Levodopa as a Treatment for Motor Fluctuations in Parkinson's Disease
Objective/Rationale:
Oral levodopa pharmacokinetics are subject to excessive within- and between-subject variability, reflecting challenges inherent to gastrointestinal delivery. Aerosol delivery of... -
LRRK2, 2011LRRK2 Physiology in Parkinson's Disease
Objective/Rationale:
Mutations in the LRRK2 gene are a common cause of genetic Parkinson’s disease. LRRK2 is highly expressed in circulating and tissue immune cells. We have recently identified that... -
Target Validation, 2011Pathway Validation of a Biased Delta Opioid Receptor Ligand for PD Symptoms & Side Effects Relief
Objective/Rationale:
Endogenous activation of the Delta opioid receptor (DOR) serves as a compensatory mechanism to alleviate Parkinson’s disease (PD) symptoms. However, DOR-mediated convulsions have... -
Dyskinesia, 2011Targeting Dramatically Activated Astrocytic Networks for Managing LID: a Target Validation Program
Objective/Rationale:
Astrocytes have long been regarded as passive partners of neurons in the central nervous system but this view has been challenged. Although astrocytes are now known to actively... -
Research Grant, 2011Identifying Markers of PD Onset and Progression in a Prospective Cohort of Patients and ASymptoms & Side Effects Carriers of LRRK2 Mutations
Objective/Rationale:
LRRK2 mutations constitute one of the most common genetic risk factors for PD. The prospective follow-up of PD patients and aSymptoms & Side Effects carriers of LRRK2 mutations...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.